Bio-Works Technologies (BIOWKS) Q2 2025 earnings summary

Executive summary

• Net sales increased by 86% year-over-year to SEK 13.1 million in Q2 2025, with strong growth across all regions, especially Europe.

• Order intake surged to SEK 27.3 million in Q2, up from SEK 12.2 million, reflecting robust demand and a solid order book.

• Operating profit improved to -7.6 MSEK from -12.0 MSEK year-over-year, with cost controls offsetting increased volumes.

• Cash flow from operating activities improved to -3.1 MSEK from -10.4 MSEK, supported by higher sales and prepayments.

• Cash and cash equivalents at period end were SEK 27.2 million, ensuring at least 12 months of operational financing.

Financial highlights

• Q2 net sales: SEK 13.1 million (up 86% year-over-year); H1 net sales: SEK 22.1 million (up 70%).

• Q2 operating profit: -7.6 MSEK; H1 operating profit: -15.4 MSEK (improved from -24.2 MSEK year-over-year).

• Q2 profit for the period: -7.3 MSEK; H1 profit: -15.3 MSEK.

• Q2 EPS: -0.09 SEK (improved from -0.18 SEK); H1 EPS: -0.19 SEK (improved from -0.49 SEK).

• Q2 order intake: SEK 27.3 million (up from SEK 12.2 million); H1 order intake: SEK 58.9 million (up from SEK 18.3 million).

Outlook and guidance

• Management anticipates continued profitable growth, leveraging a strong order book and pipeline.

• Focus remains on cost control, customer relationships, and expanding market presence.